Baseline characteristics and demographic data of patients from the SWEFOT trial
| Subset of patients with radiographs and clinical measures at baseline and 1 year | |||||
|---|---|---|---|---|---|
| Baseline characteristics: mean (±SD) | All patients (N=487)* | Radiographic subset (N=220) | Radiographic subset with progression (ΔSHS>5) (n=41) | Radiographic subset without progression (ΔSHS≤5) (n=179) | p Value (progression vs no progression) |
| Female: N (%) | 344 (70) | 156 (71) | 30 (73) | 126 (70) | 0.724 |
| Symptom duration (months) | 6.2 (4.6) | 5.9 (3.2) | 6.5 (3.6) | 5.7 (3.1) | 0.249 |
| Anti-CCP status: N (%) | 0.073 | ||||
| Positive | 275 (57) | 126 (57) | 29 (71) | 97 (54) | |
| Negative | 157 (32) | 84 (38) | 11 (27) | 73 (41) | |
| Not available | 55 (11) | 10 (5) | 1 (2) | 9 (5) | |
| RF status: N (%) | 0.118 | ||||
| Positive | 330 (68) | 142 (65) | 31 (76) | 111 (62) | |
| Negative | 152 (31) | 76 (34) | 10 (24) | 66 (37) | |
| Not available | 5 (1) | 2 (1) | 0 (0) | 2 (1) | |
| 28 Swollen joint count | 10.8 (5.3) | 10.8 (5.4) | 10.0 (5.4) | 10.7 (5.4) | 0.809 |
| 28 Tender joint count | 9.6 (6.1) | 9.3 (5.9) | 8.8 (5.2) | 9.5 (6.0) | 0.775 |
| ESR (mm/h) | 39.9 (25.9) | 41.2 (26.9) | 52.6 (33.5) | 38.5 (24.5) | 0.028 |
| CRP level (mg/L) | 33.8 (36.8) | 34.5 (36.9) | 46.2 (43.7) | 31.8 (34.7) | 0.049 |
| Patient's Global Assessment of Disease Activity (VAS 0–100 mm) score | 56 (23.9) | 55.8 (24.8) | 63.4 (21.0) | 54.1 (25.3) | 0.053 |
| DAS28 | 5.7 (1.0) | 5.7 (1.0) | 5.9 (1.2) | 5.7 (1.0) | 0.136 |
| MBDA score | 58.6 (15.1) | 59.3 (14.7) | 66.7 (12.3) | 57.6 (14.8) | 0.001 |
| SHS mean (median) | 4.5 (2) | 4.9 (2) | 6.8 (3) | 4.5 (1) | 0.039 |
*Number of missing patients for ‘All patients’ column: 28 swollen and tender joint count (n=2), ESR (n=5), CRP and Patient's Global Assessment (n=3), DAS28 (n=8), MBDA (n=185) and SHS (n=57).
anti-CCP, anticyclic citrullinated peptide; CRP, C reactive protein; DAS, disease activity score; ESR, erythrocyte sedimentation rate; MBDA, multibiomarker disease activity; RF, rheumatoid factor; SHS, Sharp/van der Heijde score; VAS, visual analogue scale.